Dovetail
The regulatory playbook

When device shortages need an Article 10a notification

An Article 10a supply interruption notification addresses a foreseeable EU device shortage or permanent supply stop that could cause serious harm. Connect your patient-impact assessment to the recipients and timing of your communication. Read the practical Q&A on scope.

When does Article 10a apply to your device supply?

Under Medical Devices Regulation (MDR), Article 10a and In Vitro Diagnostic Medical Devices Regulation (IVDR), Article 10a, a manufacturer must notify an anticipated interruption or discontinuation of device supply where it is reasonably foreseeable that it could result in serious harm, or a risk of serious harm, to patients or public health in one or more Member States. Your assessment needs to connect the supply problem to its effect on care. A late delivery alone does not establish the notification threshold.

The practical Q&A hosted by the European Commission, questions 1 to 3 explains how to apply the obligation. The obligation applies from 10 January 2025 under Regulation (EU) 2024/1860, Article 3. First check which regulation and transition provisions cover your device. The custom-made-device exclusion appears in MDR Article 10a(1), not in the IVDR wording. Legacy coverage is specifically extended to devices referred to in MDR Article 120(3a) and (3b), through Article 120(13), and IVDR Article 110(3a) and (3b), through Article 110(11), as inserted by Articles 1(4)(b) and 2(3)(e) of Regulation (EU) 2024/1860. Do not assume every device described as legacy falls within those provisions.

This guide addresses EU supply of medical devices and in vitro diagnostic devices, the tests used on human samples. It does not establish reporting requirements for Great Britain, Switzerland or other markets.

The Q&A is practical guidance, not legislation. Its opening disclaimer says that the document has not been formally endorsed by the European Commission and does not replace legal interpretation. Use it alongside the applicable regulation and your competent authority's instructions.

How should you assess a possible supply interruption?

Start with what you know about your own device, expected supply and patient population. Record the interruption you anticipate, how long it may last, available stock and whether an alternative can actually support care. The Q&A says you do not need a comprehensive market analysis, but you do need an assessment grounded in available information.

Questions 7, 9.1 and 9.2 distinguish confirmation of your own supply problem from the assessment of its potential harm. That distinction gives you a useful working sequence.

  1. Define the affected supply. Identify the model or type, relevant markets and whether you anticipate a temporary interruption or permanent stop.
  2. Establish the operational facts. Record the expected start, duration, manufacturing constraint, available stock and confidence in recovery.
  3. Assess the effect on care. Consider the intended patient population and what happens if diagnosis or treatment becomes unavailable.
  4. Check realistic alternatives. Consider expected demand, availability, infrastructure and training, rather than recording that a similar product exists.
  5. Document the decision and communication plan. Keep the rationale, supporting information, responsible person and a trigger to reassess uncertain assumptions.

The final step is our suggested working method, not a prescribed regulatory form. The underlying assessment factors come from questions 9.1 and 9.2, pages 8 and 9. You may need input from clinicians or healthcare facilities where the effect on care remains unclear.

Does an interruption shorter than 60 days need assessment?

Do not use 60 days as an automatic exemption. The Q&A describes an expected interruption longer than 60 days as a general indication. It also says that this should not prevent a manufacturer from notifying a shorter interruption if it assesses that serious harm, or a risk of serious harm, may result.

That qualification appears in question 7, page 6. A short interruption affecting an essential treatment with no adequate alternative deserves a patient-impact assessment. Duration alone cannot answer the question.

Equally, the same question describes circumstances in which manufacturers are, in principle, not required to inform. These include sufficient stock to bridge an interruption or information received from health institutions or healthcare professionals that no serious harm or risk of serious harm would occur, for example because a suitable alternative has been confirmed to meet expected demand. Record the supporting facts before relying on those circumstances.

Who must receive the notification?

Under MDR Article 10a and IVDR Article 10a, paragraphs 1 and 3, the manufacturer's communication has two routes. It goes to the competent authority of the Member State where the manufacturer or its authorised representative is established, and to the affected economic operators, health institutions and healthcare professionals the manufacturer directly supplies. Downstream economic operators must then pass the information without undue delay along their own direct-supply relationships. Under paragraph 2, the receiving authority must also inform the other Member States' competent authorities and the Commission without undue delay.

Question 4, page 5 explains the recipients. Question 13, page 10 explains the cascade and says downstream operators should preserve the manufacturer's communication rather than change, add to or paraphrase it.

Before you send anything, map the actual route.

Your supply relationshipInitial communicationDownstream handoff
You supply hospitals directlyRelevant competent authority and affected hospitals you directly supplyIdentify any other affected direct recipients
You supply an importer that supplies distributorsRelevant competent authority and affected importer you directly supplyImporter informs its direct recipients, then distributors continue the cascade
You supply through several channelsRelevant competent authority and affected direct recipients in each channelEach notified operator follows its own downstream relationships

These are simplified planning examples based on the Q&A, not an exhaustive list of supply arrangements. The manufacturer retains legal responsibility even if an authorised representative or another party helps with operational tasks, as question 2 explains.

How much notice should you give?

MDR Article 10a and IVDR Article 10a, paragraph 1, require at least six months' notice, other than in exceptional circumstances. The practical Q&A says manufacturers should inform without undue delay where exceptional circumstances prevent six months' notice. That instruction is guidance on the exception, distinct from the express statutory six-month rule. A planned business decision and an unexpected manufacturing failure need different timing assessments.

Read questions 5 and 6, pages 5 and 6. Exceptional circumstances include an inability to anticipate or confirm the interruption six months ahead, such as a sudden inability to obtain components. They do not provide a reason to wait once you have assessed the situation.

For an illustrative planned discontinuation on 1 August 2027, six months before is 1 February 2027. That calculation illustrates the standard notice period; it does not determine whether your device meets the notification threshold or whether exceptional circumstances apply.

What should a small manufacturer keep in its assessment?

Keep one record that connects the supply facts, patient-impact assessment and communication decision. The following filled example shows a practical structure. Every device, quantity, interval and conclusion in it is illustrative, not a real customer case or a regulatory determination.

Assume a manufacturer anticipates a 75-day component-related interruption for a diagnostic device. Its stock covers only part of the gap, and the proposed alternative needs equipment that affected laboratories do not currently have.

Assessment fieldIllustrative entryWhat still needs checking
Supply factsExpected interruption of 75 days; stock covers 20 daysConfirm forecast, stock allocation and affected markets
Effect on careA diagnostic service could become unavailable after stock runs outObtain clinical input on consequences for the intended population
AlternativeAnother device exists, but laboratories lack its required equipmentCheck installation time, training and capacity to meet demand
Working decisionEscalate promptly for a notification decision; do not treat the alternative as sufficient without evidenceResponsible regulatory lead completes the harm assessment
CommunicationRecord the supply-chain reason, inability to obtain a component; map competent authority, direct customers and downstream handoffsSpecify the reason in the authority form; confirm national submission route and recipients

The figures make the information gap visible; they do not create a numerical threshold. The assessment follows the factors in questions 9.1 and 9.2.

A useful internal record also names who will revisit it if the recovery date slips, stock falls faster than expected or a proposed alternative proves unavailable. These are suggested review triggers. They help you avoid leaving an uncertain first assessment untouched.

Which form and submission route should you use?

Use the Manufacturer Information Form and check the receiving competent authority's current instructions. MDR Article 10a and IVDR Article 10a, paragraph 1, require the manufacturer to specify the reasons to the competent authority. Include them in the form, as question 8, page 7 explains. Section 7 of the Manufacturer Information Form lists regulatory, supply-chain, manufacturing and other reasons; further narrative detail is voluntary. The Q&A describes the required information and acknowledges that Member States may provide additional submission instructions. Sending an internal assessment to a distributor does not replace the authority submission.

Questions 11 and 12, pages 9 and 10 explain the form and required fields.

For example, Ireland's Health Products Regulatory Authority instructions direct relevant manufacturers to complete the form and submit through its online contact form. Germany's Federal Institute for Drugs and Medical Devices instructions specify an electronic notification route and a dedicated email address. These examples show why you should confirm the route for your own authority rather than copy another country's process.

Where does this fit in your wider regulatory plan?

Connect the assessment to the event that threatens supply. If a transition or certification problem sits behind the interruption, use the MDD-to-MDR transition guide to examine that separate market-access question. If an investigation needs a structured cause analysis, the root cause analysis guide addresses that different task.

Those guides do not replace the Article 10a assessment. A supply communication, a conformity assessment and a corrective-action investigation each need their own decision and supporting evidence.

Why we built Dovetail to work differently

Your regulatory lead needs the supply forecast, clinical assumptions and communication decision in the same conversation. When each lives with a different person, an unresolved assumption can look like an agreed plan.

Dovetail's Envoy service provides embedded regulatory leadership. Bring the device scope, affected markets and open questions to a discovery call so we can discuss whether the support you need fits our work.

Sources and further reading

Article 10a notification FAQs

Use these answers to check your assessment and communication plan.

No. MDR and IVDR Article 10a(1) concern an anticipated interruption or discontinuation where it is reasonably foreseeable that it could result in serious harm, or a risk of serious harm, to patients or public health in one or more Member States. The MDR excludes custom-made devices. Legacy coverage is limited to the devices referred to in MDR Article 120(3a) and (3b) and IVDR Article 110(3a) and (3b). MDR Article 10a and IVDR Article 10a. Q&A, questions 1 to 3

No. Question 7 describes more than 60 days as a general indication and says this should not prevent notification of a shorter interruption if the manufacturer assesses that serious harm, or a risk of serious harm, may result. Assess patient impact rather than duration alone. Q&A, question 7

The manufacturer retains legal responsibility. The Q&A allows operational help from an authorised representative, another economic operator or a third party, but says the manufacturer cannot delegate its legal responsibility for the task. Q&A, question 2

Article 10a(1) requires at least six months' notice other than in exceptional circumstances. Questions 5 and 6 describe exceptional circumstances where a manufacturer cannot anticipate or confirm an interruption at least six months before it starts. In those circumstances, the Q&A says to inform the relevant recipients without undue delay. MDR Article 10a and IVDR Article 10a. Q&A, questions 5 and 6

Pass the manufacturer's information without undue delay to the relevant operators, health institutions and healthcare professionals you directly supply. The Q&A says to preserve the communication rather than change, add to or paraphrase it. MDR Article 10a and IVDR Article 10a. Q&A, question 13

The existence of another device does not by itself establish that patient care can continue. The Q&A includes availability, ability to meet demand, required infrastructure and training among the assessment factors. Document why the alternative is suitable in the affected markets. Q&A, questions 9.1 and 9.2

Give your supply assessment a clear next step

Bring your device scope, affected markets and unresolved questions. We can discuss whether our regulatory support fits the work you need.

About the author

Dr Spencer Todd is the CEO and co-founder of Dovetail, a regulatory partner for medical device companies. Before founding Dovetail, he spent years at the FDA and as a medical device consultant.